Trevi Therapeutics Moves Forward with Haduvio for Chronic Cough
Trevi Therapeutics Develops Novel Treatment for Chronic Cough
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is making strides in the fight against chronic cough associated with idiopathic pulmonary fibrosis (IPF). This clinical-stage biopharmaceutical company recently completed enrollment in its Phase 2b CORAL trial, which investigates the effectiveness of Haduvio™, an oral extended-release formulation of nalbuphine. Expectations are set high with topline results anticipated to arrive in the first half of 2025.
Understanding the CORAL Trial
The CORAL trial is designed to assess Haduvio's efficacy against chronic cough, a common yet debilitating symptom in IPF patients, with a significant sample size of approximately 160 individuals involved. The trial utilizes a double-blind, randomized, placebo-controlled approach over a span of six weeks, with three varying doses of Haduvio - 27mg, 54mg, and 108mg - compared directly against a placebo.
Research Goals and Endpoint Measurements
Leveraging a patient-focused design, the primary efficacy endpoint measures the relative change in 24-hour cough frequency by using an objective cough monitor at the end of Week 6, comparing Haduvio’s impact to that of the placebo. This analytic method is crucial due to the chronic nature of cough experienced by IPF patients, which often complicates their overall health condition.
The Challenge of Chronic Cough in IPF Patients
Chronic cough in patients with IPF is a significant concern, affecting up to 85% of this population. With around 140,000 individuals diagnosed with IPF in the United States, the persistent coughing can occur as often as 1,500 times daily, leading to increased health risks, including lung transplant needs. Current treatments have proven largely ineffective, highlighting the urgent need for innovative solutions.
Impact on Quality of Life
The implications of chronic cough go beyond physical health, severely impacting the social, emotional, and psychological well-being of patients. Many individuals report feelings of embarrassment, social withdrawal, and disturbances in their daily lives, underlining the importance of successful treatment options.
Haduvio's Mechanism of Action
Haduvio acts on both central and peripheral opioid receptors by functioning as a kappa agonist and mu antagonist (KAMA). This dual action may provide a comprehensive approach to control cough symptoms, aiming to alleviate the persistent discomfort experienced by those with chronic cough and IPF.
Significance of the Upcoming Results
The data gathered from the CORAL trial will be pivotal in shaping Trevi's subsequent steps in the development of Haduvio. The findings will inform optimal dosing strategies to advance into pivotal Phase 3 clinical trials, alongside fulfilling the critical needs of patients suffering from chronic cough.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. specializes in developing innovative therapies for unmet medical needs in serious diseases. The company’s portfolio includes Haduvio, targeted at addressing chronic cough related to both idiopathic pulmonary fibrosis and refractory chronic cough, a condition affecting millions of adults in the U.S., causing significant social and health-related challenges.
The Future of Chronic Cough Treatment
As the completion of enrollment in the CORAL trial marks a significant milestone, Trevi Therapeutics is eager to share the findings of this important research as they continue to explore potential therapies. With no current approved treatments addressing this specific indication, the outcomes might redefine the chronic cough management landscape.
Frequently Asked Questions
What is the CORAL trial?
The CORAL trial is a Phase 2b clinical study evaluating the efficacy of Haduvio in treating chronic cough in patients with idiopathic pulmonary fibrosis.
How many patients were enrolled in the trial?
Approximately 160 patients with chronic cough associated with IPF were enrolled in the CORAL trial.
What is the primary endpoint of the trial?
The primary endpoint is the relative change in 24-hour cough frequency at the end of Week 6 compared to baseline.
What is Haduvio?
Haduvio is an investigational therapy that combines nalbuphine extended-release, targeting cough reflex pathways to provide symptom relief.
When are the topline results expected?
Topline results from the CORAL trial are anticipated to be reported in the first half of 2025.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.